In many countries, including both Australia and New Zealand, recombinant activated factor VII (rFVIIa, Novoseven, Novo Nordisk, Bagsvaerd, Denmark) is licensed for the prevention and treatment of bleeding in patients with inhibitors to factors VIII or IX, factor VII deficiency and Glanzman's thrombaesthenia. Exclusive to these conditions, there has been increasing off-label use of rFVIIa in critical bleeding 1 , with a number of case reports and series describing its efficacy in non-haemophilia patients. RFVIIa has been studied prospectively in a variety of surgical situations including cardiac surgery, liver resection and prostatectomy as well as emergency situations following trauma and in obstetrics [2] [3] [4] [5] [6] [7] [8] . In trauma and intracerebral haemorrhage, prospective randomised studies have demonstrated a statistically significant reduction in red cell transfusion and a reduction in bleeding, but not significant outcome benefits 6, 9 , while its pre-emptive use for liver transplantation and other procedures has not shown superiority over placebo 10 .
Concerns with the safety of rFVIIa have stemmed from isolated reports of fatal thrombotic events after the infusion of rFVIIa, including during cardiac surgery 11 . A review of adverse events reported to the USA Food and Drug Authority suggests that most thromboembolic events are associated with the use of rFVIIa for "off-label" indications, with serious morbidity and mortality 12 . Thrombotic events after rFVIIa use have also been compared to the use of other bypassing coagulation agents, such as factor VIII inhibitor bypass activity and appear to be three times more frequent for rFVIIa 13 .
The aim of this study was to utilise data collected through two separate registries to analyse the association of rFVIIa with adverse events, in particular thrombo-embolic events.
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SUMMARy
We investigated whether there was an association between recombinant activated factor VII (rFVIIa) use in cardiac surgery and thromboembolic events by comparing cases in two medical registries. The incidence of thromboembolic events in patients undergoing cardiac surgery (except isolated coronary artery bypass grafts) who had received rFVIIa and were entered into the Australian and New Zealand Haemostasis Registry was compared with the background incidence in patients entered in the Australasian Society for Cardiac and Thoracic Surgeons database. Mortality, length of hospital stay and thromboembolic complications such as stroke, perioperative myocardial infarction and pulmonary embolism data were analysed.
A total of 705 patients in the Registry were compared with 6554 patients in the Thoracic Surgeons database. The use of rFVIIa was independently associated with higher mortality (odds ratio 2.55, P <0.001) and longer hospital stay (odds ratio 1.54, P=0.020). However, multiple regression analyses showed no independent association between rFVIIa and stroke (odds ratio 1.0, P=0.994) or perioperative myocardial infarction (odds ratio 0.29, P=0.053), while the use of rFVIIa was associated with fewer pulmonary emboli (odds ratio 0.02, P <0.001).
These findings indicate that patients who received rFVIIa had increased mortality and length of hospital stay, as expected, but that rFVIIa use was not associated with an increased incidence of stroke or perioperative myocardial infarction. In the absence of randomised controlled clinical trials, this analysis suggests that the off-label use of rFVIIa in cardiac surgery does not significantly increase thromboembolic events.
METHoDS
All patients who received rFVIIa during cardiac surgery and who were reported to the Australian and New Zealand Haemostasis Registry (ANZHR) were included in the analysis. The ANZHR collects data from patients without haemophilia treated with rFVIIa at participating hospitals throughout Australia and New Zealand. The ANZHR has been established by Monash University, Victoria with financial support in the form of an unrestricted educational grant from Novo Nordisk Pharmaceuticals Ltd. The ANZHR began receiving data in May 2005 but includes retrospective cases dating back to 2000. It is estimated from Novo Nordisk sales data that this represents approximately 85% of rFVIIa use in Australia and New Zealand. Forty-six hospitals from all states and territories of Australia and New Zealand are currently contributing data to the registry, of which 21 are cardiac surgery centres. Patients who received rFVIIa were identified by local investigators through pharmacy or haematology records. Submitting hospitals are required to commit to supplying complete datasets. This commitment, audited by the Department of Epidemiology and Preventive Medicine, Monash University, limits bias and prevents the reporting of only positive experiences. Database design and data collection details for the ANZHR have been previously described 1, 14 .
The ANZHR data collection forms together with the data dictionary containing definitions are available at the Haemostatsis Registry website: www.med.monash.edu.au/epidemiology/traumaepi/ haemostatsis.html Patients entered into the Australasian Society for Cardiac and Thoracic Surgeons (ASCTS) Cardiac Surgery database over the same time period were used as the comparison group. Patients in the ASCTS group who received rFVIIa were removed from the ASCTS group. These patients were all present in the ANZHR. The ASCTS database project has prospectively collected data on patients undergoing cardiac surgery at all six publicly funded cardiac surgical units in Victoria since July 2001. The ASCTS database contains detailed information collected during the perioperative period on patient demographics, risk factors, operative details, postoperative hospital course and morbidity and mortality outcomes. The information is collected prospectively for all patients as part of clinical care and follow-up by surgeons, perfusionists, resident medical officers and database managers. Database design and data collection have been previously described 15 . The ASCTS project obtains informed consent from each participant in relation to their information being used as part of the project.
Ethical approval for the two medical registries has been previously documented 1, 14 . It is voluntary for a hospital to join but case inclusions are mandatory once joined for both registries.
Patients
Data on patients undergoing all cardiac surgery between January 2001 and June 2008 were extracted. Patients with missing data were excluded. Patients undergoing coronary artery bypass grafts (CABG) have been shown to have significantly lower mortality when compared to other types of cardiac surgery 16 . As the ASCTS database contained a significantly higher proportion of patients undergoing CABGs than the ANZHR (Table 1) , patients undergoing CABG were removed from both registries to establish greater equivalence between the datasets.
The urgency of procedures was stratified according to the database definitions. An elective procedure was one that could be deferred without increased risk of compromised cardiac outcome. An emergency procedure was unscheduled surgery required in the next available operating theatre on the same day due to refractory angina or cardiac compromise. Urgent procedures were those where all of the following conditions were met: a nonelective status, non-emergency status or procedure required during the same hospitalisation in order to minimise chance of further clinical deterioration. Salvage procedures were those where the patient was undergoing cardiopulmonary resuscitation en route to the operating room prior to surgical incision.
Length of hospital stay and mortality were recorded. Stroke and perioperative myocardial Pulmonary emboli were diagnosed with either a high probability ventilation-perfusion scan or on computed tomography-pulmonary angiogram. A massive transfusion was defined as the administration of ≥5 units of packed red blood cells.
Analysis
All analyses were performed using Stata 10.1 (Statacorp LP, College Station, Texas, USA, 2009). Demographic features, type of surgery, amount of blood transfused and use of rFVIIa were entered into multiple regression models developed using a stepwise selection procedure and a backwards elimination procedure before undergoing assessment for clinical and biological plausibility. Results were reported as odds ratios (oR) with 95% confidence intervals (CI). A P value of <0.05 was considered to be statistically significant. Continuous data were reported as mean ± standard deviation (for symmetric data) and median ± interquartile range for asymmetric data. The analysis was repeated for the subgroup of patients who did not undergo CABG.
RESULTS
Between January 2001 and June 2008, the ANZHR included 2043 cases, of which 854 cases (42%) received rFVIIa for uncontrollable haemorrhage associated with cardiac surgery. over the same period, the ASCTS database included a total of 18481 cases. Following exclusion of patients undergoing isolated CABGs only, there were 705 patients in the ANZHR who were compared to 6554 patients in the ASCTS group. Demographic and risk factor comparison of the two groups are presented in Table 2 , while adverse events and outcomes are presented in Table 3 . Demographics and clinical features independently associated with adverse events are summarised in Table 4 .
Mortality
Multiple regression analysis showed the use of rFVIIa was independently associated with significantly higher mortality (oR 2.55, P <0.001, CI 1.57 to 4.15). In addition, other factors significantly associated with higher mortality were increased age (oR 2.01, P=0.001, CI 1.21 to 3.07), the presence of cerebrovascular disease (oR 2.18, P=0.001, CI 1.39 to 3.42), emergency surgery (oR 5.43, P <0.001, CI 3.69 to 7.98), salvage surgery (oR 16.76, P <0.001, CI 6.16 to 45.54) and massive transfusion (oR 4.03, P <0.001, CI 2.72 to 5.99). Length of hospital stay The use of rFVIIa was also associated with increased length-of-stay (oR 1.54, P=0.020, CI 1.07 to 2.21). other factors associated with longer lengthof-stay were the presence of peripheral vascular disease (oR 1.82, P=0.001, CI 1.27 to 2.62), the use of anticoagulants (oR 2.27, P <0.001, CI 3.61 to 6.14), urgent surgery (oR 4.71, P <0.001, CI 3.61 to 6.14) and massive transfusion (oR 2.40, P <0.001, CI 1.91 to 3.02).
Stroke
The use of rFVIIa was not significantly associated with stroke (oR 1.00, P=0.994, CI 0.56 to 1.78). Significant independent associations with stroke were increased age (oR 1.71, P=0.025, CI 1.07 to 2.73), the presence of lung disease (oR 1.87, P=0.034, CI 1.05 to 3.34), emergency surgery (oR 2.73, P <0.001, CI 1.74 to 4.30) and massive transfusion (oR 2.86, P <0.001, CI 1.91 to 4.30).
Perioperative myocardial infarction
The use of rFVIIa was not significantly associated with perioperative myocardial infarction (oR 0.29, P=0.053, CI 0.08 to 1.01). Significant associations with perioperative myocardial infarction were found to be female gender (oR 2.29, P=0.010, CI 1.21 to 4.32) and massive transfusion (oR=2.74, P=0.006, CI 1.34 to 5.61).
Pulmonary emboli
The use of rFVIIa was associated with slightly fewer pulmonary emboli (oR 0.02, P <0.001, CI 0.01 to 0.08). Significant associations with pulmonary emboli were found to be urgent surgery (oR 2.84, P <0.001, CI 2.10 to 3.84) and massive transfusion (oR 2.75, P <0.001, CI 2.15 to 3.52).
DISCUSSIoN
The analysis of adverse events associated with rFVIIa has been difficult to interpret, given the extremely critical nature of patients receiving the product. This study demonstrated that patients receiving rFVIIa had an approximately 7% rate of stroke, which is similar to rates demonstrated in previous studies 9, 12 . We have shown that this high rate is related more to patient demographics and procedures associated with the critical nature of the patient rather than the use of rFVIIa. Moreover, there was no significant difference even in the unadjusted rate of perioperative myocardial infarction between the groups, and patients treated with rFVIIa had a slightly lower rate of pulmonary emboli than those in the ASCTS database.
This observational study was not designed to examine the determinants of death or other adverse outcomes. As expected, mortality and length-ofstay were significantly higher in patients receiving rFVIIa, with rFVIIa and massive transfusions independently associated with significantly higher mortality. In Australasia, as in many parts of the world, rFVIIa is generally used only when conventional therapy fails and consequently these patients have the highest risk of death. The rates of mortality and length-of-stay in the rFVIIa group were similar to previous reports on complex cardiac surgical procedures that required high volumes of blood transfusion and rFVIIa 17 .
Myocardial infarction and stroke have been widely used as measures of adverse events in patients treated with rFVIIa 9, 12, 14, 18, 19 . This study has shown that massive transfusions, rather than rFVIIa, were associated with the higher rates of arterial complications. This association is difficult to interpret retrospectively. Moreover, the study may have had insufficient power to exclude a small effect of rFVIIa. The definitions of 'stroke', using neurological deficits and perioperative myocardial infarction, using cardiac markers, are likely to include not only thromboembolic events but also patients experiencing vascular ischaemia due to hypoperfusion. In the absence of angiographic studies, the distinction between hypoperfusionrelated ischaemia versus thrombosis for these two conditions is impossible. The significant association of these adverse events with massive transfusion, and not rFVIIa, suggests that many of these complications reflected hypoperfusion, rather than thrombotic events.
Multiple case reports and one randomised, placebo-controlled study in adult cardiac surgery patients 2 have found an association between the use of rFVIIa and a reduction in blood product consumption. In addition to the significant associations with adverse events in this study, massive transfusions in the setting of cardiac surgery have been associated with increased mortality and morbidity 20, 21 . Earlier use of rFVIIa in critical bleeding may therefore be justified in an effort to reduce massive transfusions and their associated morbidity.
Recent case control studies have included relatively small numbers of patients [22] [23] [24] and have attempted to reduce differences between the cases and controls through propensity score analysis. Due to the smaller numbers and low rates of adverse events, none of these studies was able to make definitive conclusions regarding the association of rFVIIa with adverse events. While our patients were unmatched, the larger numbers of patients included in each group allows a more accurate assessment of baseline adverse event rates.
The tracking of adverse outcomes in off-label application of medications is challenging 25 , with estimates based on the Food and Drug Authority Adverse Event Reporting System significantly underrepresenting actual occurrences 12 . The denominator relating to these adverse events (i.e. the number of uses where adverse events are absent) also remains unknown. our study utilised data from two large medical registries and is unique in that participating hospitals are required to submit complete datasets. The requirements of both registries to enrol all patients ensure the entire population of patients is included, resulting in a clear numerator and denominator without the possibility of selection bias.
A definitive prospective, placebo-controlled, double-blinded, randomised control trial studying rFVIIa is unlikely in the short-to medium-term. The reasons for this have been previously highlighted 25 and include the current size of the market, high costs and the risks of morbidity and mortality. Furthermore, the critical situation in which rFVIIa is often administered creates difficulties in study design and is challenging for ethical committee approvals.
These problems have prompted calls for metaanalyses and the standardisation of outcome reporting for off-label rFVIIa. The limitations of retrospective studies and meta-analyses were recently highlighted in a Canadian review of the off-label use of rFVIIa in cardiac surgery 26, 27 . While supported by its size and high inclusion rates, this review was limited by incomplete evaluation of adverse effects due to deficiencies in reporting. The use of clinical outcome registries can assist in overcoming such deficits. Patient registries act as surveillance systems to monitor a population for any occurrence of an unexpected or harmful event. This active surveillance approach is likely to be more useful than passive event detection. By providing a system for reporting these adverse events and by gathering information on the exposed population, registries can help both to quantify the risk and to properly attribute it.
The major limitation of this study and others in analysing off-label use of rFVIIa continues to be the lack of guidelines and uniform practice. Doses and timing of the administration of rFVIIa remain variable. While the size of the two registries can allow some correction for bias associated with the variety of clinical practice, using two registries designed for different purposes results in a high variability in patient demographics. In the absence of massive transfusion guidelines, the use of fluids, blood and blood products, surgical procedures and postoperative care are another potential source of bias. Data on a wider range of adverse events such as deep venous thromboses, acute lung injury, multiorgan failure etc are also not routinely collected by a general cardiac surgery registry and could not be analysed. However, it has been previously shown that the event-rate of such adverse effects associated with the use of rFVIIa does not appear to be higher than those reported in complex cardiac surgical procedures requiring significant transfusions 28 .
In conclusion, this report does not support an association between the use of rFVIIa during cardiac surgery and an increase in stroke, perioperative myocardial infarction or pulmonary embolism. In the absence of randomised, controlled clinical trials, this analysis suggests that the offlabel use of rFVIIa in cardiac surgery does not significantly increase these thromboembolic events.
